Payment overview · 2025
General Payments
$3,756.61
146 reported records · 19 companies
Healthcare provider profile · identity verified
Eric Christoff, M.D.
Allopathic & Osteopathic Physicians|General Practice · CHICAGO, IL · NPI 1245287317
Verified facts
What the public records show
CMS Open Payments records show Eric Christoff, M.D. received $3,756.61 in general payments during 2025 across 146 reported records.
ViiV Healthcare Company accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Mounjaro.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $1,325.05 | 35.3% | 49 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $616.38 | 16.4% | 15 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $595.58 | 15.8% | 26 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $260.96 | 7.0% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $185.62 | 4.9% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $148.57 | 4.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.52 | 3.4% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $103.24 | 2.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.31 | 1.9% | 3 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $61.99 | 1.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.43 | 1.4% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $33.24 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.88 | 0.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.60 | 0.8% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $29.92 | 0.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.00 | 0.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $24.11 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.90 | 0.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.31 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,756.61 | 146 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $616.38 | 15 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $616.38 | 15 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $499.42 | 19 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $439.81 | 19 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $240.61 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $185.62 | 8 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $162.40 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $148.57 | 7 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $144.17 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $131.40 | 5 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $129.56 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $124.58 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $103.24 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.40 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $73.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $73.31 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $73.31 | 3 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $61.99 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.43 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 127 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
127 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
178 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Descovy | Emtricitabine/Tenofov Alafenam | 178 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 36 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 127 | 15 |
| Bupropion Xl | Bupropion Hcl | 91 | 18 |
| Gabapentin | Gabapentin | 85 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 22 |
| Pregabalin | Pregabalin | 68 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Omeprazole | Omeprazole | 57 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 16 |
| Mirtazapine | Mirtazapine | 53 | 11 |
| Metformin Hcl | Metformin Hcl | 51 | 13 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Famotidine | Famotidine | 43 | 11 |
| Losartan Potassium | Losartan Potassium | 42 | 12 |
| Isentress Hd | Raltegravir Potassium | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lisinopril | Lisinopril | 25 | 11 |
| Tivicay | Dolutegravir Sodium | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Risperidone | Risperidone | 20 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,756.61 · 146 records | ViiV Healthcare Company | ABRYSVO, APRETUDE, BEXSERO, BRIXADI, Biktarvy, CABENUVA, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, DELSTRIGO, DOVATO, EGRIFTA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, INSPIRE, MAVYRET, MOUNJARO, Mytesi, OTEZLA, PIFELTRO, PREVNAR 20, REPATHA, REXULTI, RUKOBIA, SHINGRIX, SUBLOCADE, TROGARZO, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error